<DOC>
	<DOCNO>NCT00320255</DOCNO>
	<brief_summary>The purpose study learn whether apixaban well-tolerated acceptable anticoagulant therapy , administer patient advanced metastatic cancer increase risk venous thromboembolic event . Demonstration favorable benefit : risk profile could lead significant reduction serious sometimes fatal complication ongoing cancer treatment .</brief_summary>
	<brief_title>A Phase 2 Pilot Study Apixaban Prevention Thromboembolic Events Patients With Advanced ( Metastatic ) Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Key Recipients either first secondline chemotherapy advance metastatic lung , breast , gastrointestinal , bladder , ovarian , prostate cancer myeloma , select lymphoma , cancer unknown origin Able begin study medication ≤6 week start either first secondline chemotherapy . Expected course chemotherapy must ≥ 90 day start chemotherapy Per Protocol Amendment 5 , patient receive bevacizumab eligible participate , provide bevacizumab use indication approve local country law Key Women pregnant , breastfeed History deep vein thrombosis pulmonary embolism Active bleeding high risk bleed Metastatic brain cancer Familial bleed diathesis Serious hemorrhage require hospitalization , transfusion , surgical intervention within 4 week study entry Expected survival &lt; 6 month Eastern Cooperative Oncology Group performance status ≥3 . Candidates bone marrow transplantation within 12week treatment period 30day followup period Uncontrolled hypertension ( systolic blood pressure &gt; 200 mm Hg and/or diastolic blood pressure &gt; 110 mm Hg Coagulopathy ( international normalize ratio &gt; 1.5 platelet count &lt; 100*10^9/L ) yet receive chemotherapy &lt; 50*10^9/L receive chemotherapy ) . Platelet count must &gt; 100*10^9/L start study medication One following : alanine aminotransferase &gt; 3 time upper limit normal ( ULN ) , total bilirubin &gt; 2*ULN , calculate creatinine clearance &lt; 30 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>anticoagulant</keyword>
</DOC>